Core Viewpoint - Rongchang Biopharmaceutical has signed an exclusive licensing agreement with AbbVie for the novel PD-1/VEGF bispecific antibody drug RC148, which is expected to significantly enhance the company's financial position and growth prospects [3][20]. Group 1: Licensing Agreement Details - The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China, with Rongchang receiving an upfront payment of $650 million (approximately 4.5 billion RMB) [3][7]. - The total potential transaction value could reach $4.95 billion (approximately 34.5 billion RMB), including milestone payments and royalties based on net sales [3][7]. - This transaction marks a record for Rongchang in terms of both upfront payment and total deal value, surpassing previous agreements [7][20]. Group 2: Industry Trends - The number of BD (business development) licensing agreements for Chinese innovative drugs has surged, with transactions increasing from 85 in 2023 to 157 in 2025, reflecting a compound annual growth rate of 35.9% [9]. - The total transaction value for these agreements is projected to rise from $32 billion in 2023 to $135.7 billion in 2025, representing over a threefold increase [11]. - The average upfront payment has also seen significant growth, increasing from $2.5 billion to $7 billion, a rise of 180% [11][13]. Group 3: Company Financial Performance - Rongchang's revenue for the first three quarters of 2025 reached 1.72 billion RMB, marking a year-on-year growth of 42.27% [14]. - Despite the revenue growth, the company has reported net losses exceeding 1 billion RMB from 2022 to 2024, with a reduced loss of 551 million RMB in the first three quarters of 2025 compared to 1.071 billion RMB in the same period of 2024 [15][16]. - The anticipated upfront payment from the AbbVie agreement is expected to further improve Rongchang's profitability and cash reserves, potentially leading to profitability in 2026 if the payment is fully received [16].

证券之星消息，1月14日生物制品板块较上一交易日下跌0.9%，荣昌生物领跌。当日上证指数报收于 4126.09，下跌0.31%。深证成指报收于14248.6，上涨0.56%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688488 | 艾迪药业 | 19.83 | 16.72% | 24.24万 | | 4.62亿 | | 301393 | 吴帆生物 | 57.38 | 4.35% | 4.79万 | | 2.72亿 | | 688185 | 康布诺 | 71.99 | 4.17% | 4.93万 | 1 | 3.55亿 | | 688765 | 末元生物 | 85.30 | 3.77% | 7.93万 | | 6.78亿 | | 300142 | 沃森生物 | 12.77 | 3.74% | 129.35万 | | 16.81亿 | | 688105 | 诺唯赞 | 22.89 | 2.65% | 6.98万 | | 1.62亿 | | 301 ...

Core Viewpoint - The innovative drug sector is experiencing a decline, with several key stocks and ETFs showing significant drops in value, indicating a potential shift in market sentiment towards this industry [1][2]. Group 1: Stock Performance - Rongchang Biopharmaceutical has seen a decline of over 10% in its stock price [1]. - Other companies such as Baile Tianheng, Xinlitai, and Maiwei Biopharmaceutical-U have also dropped more than 3% [1]. - Multiple innovative drug-related ETFs have decreased nearly 2% in value [1]. Group 2: Market Analysis - Some brokerages suggest that core assets in the innovative drug sector will continue to appreciate, highlighting emerging opportunities in small nucleic acids and in vivo CAR technologies [2]. - The long-term trend of innovative drug business development (BD) is seen as a pathway for Chinese innovative drug capabilities to gain recognition on the global stage [2]. - Core assets that have been licensed to multinational corporations (MNCs) are expected to realize their value as clinical progress continues [2]. - Future focus should remain on cutting-edge technology platforms and closely monitor advancements in clinical data [2].

Core Insights - The PD-1/VEGF dual antibody sector is experiencing a divergence, with Yiming Biotech facing setbacks due to the return of its PD-L1/VEGF dual antibody by partner Axion, while Rongchang Biotech secured a significant licensing deal worth $5.6 billion with AbbVie, highlighting the increasing differentiation within the dual antibody space and outlining the core investment theme for 2026: certainty [1][2] Group 1: Investment Trends - The investment landscape in the pharmaceutical sector is shifting from a focus on broad-based licensing deals to a preference for certainty in value, emphasizing three core anchors: expectation certainty, product certainty, and performance certainty [2][6] - The previous trend of "BD is king" in 2025 led to a surge in licensing deals, but the market is now recalibrating its valuation logic, moving away from blind enthusiasm towards a more rational assessment of the feasibility of these deals [1][2] Group 2: Expectation Certainty - Expectation certainty involves a rational evaluation of the feasibility of BD transactions rather than blind pursuit of total deal amounts, as the probability of new drugs progressing from early clinical stages to market approval is only 7.9% [3][4] - The competitive landscape in the PD-1/VEGF dual antibody sector shows that not all players can achieve their expected value due to overlapping targets and indications, mirroring past trends in the PD-1 monoclonal antibody market [3][4] Group 3: Product Certainty - Product certainty focuses on the potential for substantial sales post-launch, with products that have clear growth logic expected to command higher valuations [5][6] - WanTai Biotech's nine-valent HPV vaccine, priced at 499 yuan per dose (40% of imported vaccines), is positioned for significant market penetration, while Innovent Biologics' Ma Shidu peptide faces challenges due to increased competition and pricing pressures, leading to diminished commercial value [5][6] Group 4: Performance Certainty - Performance certainty seeks companies and sectors with clear growth or recovery expectations, as the essence of investment is capturing expectation differences [7][8] - WuXi AppTec's profit forecast for 2025 indicates a significant growth of 41.33% year-on-year, reflecting its foundational role in the global pharmaceutical supply chain and a potential recovery in valuation due to increased R&D investments [7][8] - The vaccine sector is also poised for recovery, with domestic companies expected to benefit from a broad replacement market and initial overseas expansion, indicating a favorable investment outlook [7][8]

摩根大通发表报告指，荣昌生物与艾伯维就RC148达成独家授权许可协议，协议包含6.5亿美元的首付 款，最高达49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华区以外地区净销售额的两位数 分级特许权使用费。摩通认为，今次合作带来惊喜，可能提振市场对中国生物科技和制药领域的整体信 心，因该行先前对此事件发生机率评估偏低，且未纳入模型考量。交易亦反映RC148的竞争优势，预期 其在非小细胞肺癌(NSCLC)一线治疗的关键数据将于五月底ASCO会议期间公布。该行将荣昌生物目标 价由77港元上调至116港元，评级由"中性"上调至"增持"。 ...

Core Viewpoint - The total margin balance of the Sci-Tech Innovation Board reached 288.907 billion yuan on January 13, showing an increase of 1.127 billion yuan compared to the previous trading day [1] Group 1: Margin Balance - The financing balance amounted to 287.888 billion yuan, increasing by 1.178 billion yuan from the previous trading day [1] - The margin trading balance decreased to 10.19 billion yuan, down by 0.051 billion yuan from the previous trading day [1] Group 2: Individual Stock Performance - On January 13, 311 stocks on the Sci-Tech Innovation Board experienced net financing inflows, with 10 stocks having net inflows exceeding 100 million yuan [1] - Kingsoft Office topped the list with a net financing inflow of 276 million yuan [1] - Other notable stocks with significant net financing inflows include Chengdu Xian Dao, Zhongke Xingtu, Zhongxin International, Rongchang Bio, Western Superconducting, and Green Harmony [1]

Group 1 - The Hong Kong stock market saw a strong performance in the early session on January 14, with the pharmaceutical sector leading the gains. The Hong Kong Innovative Drug ETF (159567) rose by 2.52%, with trading volume quickly surpassing 300 million yuan [1] - The Hong Kong Innovative Drug ETF (159567) has experienced a rebound since the beginning of 2026, with a cumulative increase of over 11% from January 5 to January 13 [1] - The ETF closely tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index (987018), which reflects the performance characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [1] Group 2 - On January 12, the 44th JPMorgan Global Healthcare Conference officially opened in the United States, attracting significant attention from the biopharmaceutical industry. Several domestic innovative drug companies participated, with seven companies presenting at the main venue [2] - Huatai Securities noted that the liquidity in the Hong Kong innovative drug sector has significantly improved since the beginning of 2026, and the JPMorgan conference has provided a platform for domestic pharmaceutical companies to advance overseas business development (BD) collaborations [2] - The ongoing liquidity recovery is expected to lead to a clear innovative drug beta market, with external demand-driven CXO companies likely to achieve performance that exceeds expectations, resonating with innovative drugs [2]

Core Insights - The collaboration between AbbVie and Rongchang Biopharma marks a significant shift in the global oncology treatment landscape, highlighting the trend of "Chinese innovation + global market" in drug development [1][2] Group 1: Collaboration Details - AbbVie and Rongchang Biopharma signed an exclusive licensing agreement for the development, production, and commercialization of RC148, a bispecific antibody targeting PD-1 and VEGF [1] - Rongchang Biopharma will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with a tiered royalty on net sales outside Greater China [1][2] Group 2: Market Implications - The deal allows Rongchang Biopharma to accelerate clinical trials for RC148 in China and globally, while also supporting the development of other pipelines [2] - AbbVie aims to enhance its product portfolio in immuno-oncology, particularly in the emerging PD-1/VEGF bispecific antibody space, which could improve its competitiveness in solid tumor treatments [2] Group 3: Industry Trends - The PD-1/VEGF bispecific antibody represents a new class of cancer therapies that may overcome tumor resistance mechanisms by simultaneously blocking PD-1 and VEGF [3][5] - Chinese companies are leading in this field, with significant advancements and approvals, such as the launch of Ak112/Ivonescimab by Kangfang Biopharma, which is the first bispecific antibody combining tumor immunity and anti-angiogenesis mechanisms [3] Group 4: Broader Market Dynamics - The global interest in PD-1/VEGF bispecific antibodies is rising, with several Chinese firms successfully engaging in business development (BD) transactions, reflecting the increasing recognition of Chinese innovative drug assets by multinational pharmaceutical companies [6][7] - In 2025, the total value of Chinese innovative drug licensing transactions exceeded $130 billion, accounting for 49% of the global total, indicating a significant shift in the global pharmaceutical landscape [7][8] Group 5: Future Outlook - The increasing number of approved innovative drugs in China, along with the growing bargaining power of Chinese companies in licensing agreements, suggests a transition from a "follow" to a "lead" position in global pharmaceutical innovation [8][10] - The ability of Chinese companies to negotiate favorable terms in BD transactions is becoming crucial, emphasizing the importance of pipeline strength, data quality, and structured deal design [9][10]

Core Insights - The collaboration between AbbVie and Rongchang Biopharma marks a significant shift in the global oncology treatment landscape, focusing on the development of the bispecific antibody RC148 targeting PD-1 and VEGF [1][2] Group 1: Collaboration Details - AbbVie and Rongchang Biopharma signed an exclusive licensing agreement for RC148, granting AbbVie rights outside Greater China for development, production, and commercialization [1] - Rongchang Biopharma will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with a tiered royalty on net sales outside Greater China [1][2] Group 2: Market Implications - This deal exemplifies the "China innovation + global market" model, providing Rongchang Biopharma with substantial cash flow to accelerate clinical trials for RC148 and support other pipeline developments [2] - The partnership with a top-tier oncology company like AbbVie enhances Rongchang Biopharma's brand and bargaining power in international markets, while AbbVie benefits from expanding its immuno-oncology product portfolio [2] Group 3: Bispecific Antibody Landscape - RC148 represents a new class of cancer therapies aimed at simultaneously blocking PD-1 and VEGF, potentially overcoming tumor resistance mechanisms [5] - The PD-1/VEGF bispecific antibody field is gaining traction, with several Chinese companies, including Kangfang Biopharma and Junshi Biosciences, making significant advancements and entering clinical trials [6][7] Group 4: Industry Trends - The Chinese innovative drug sector is experiencing a surge in licensing deals, with over $130 billion in total transaction value in 2025, surpassing the U.S. for the first time [10] - Factors driving this trend include the impending patent cliff for major drugs and declining R&D efficiency among multinational pharmaceutical companies, leading them to seek external innovations [10][11] Group 5: Future Outlook - The Chinese pharmaceutical industry is transitioning from a follower to a leader in innovation, with a clear direction for future development [14] - Companies are focusing on building a comprehensive value creation logic recognized by international partners, enhancing their negotiation power in licensing agreements [12][13]

证券时报记者 梁谦刚 国家药监局药品注册管理司副司长蓝恭涛表示，这些创新药在我国上市，使我国患者可以更早地获得全球生物医 药创新最新成果的治疗，标志着我国生物医药领域实现从跟跑到并跑、部分领跑的跨越，说明我国已成为全球生 物医药创新领域的重要力量。 创新药公司的亮眼业绩，也侧面反映产业的高景气度。1月13日，A股创新药龙头公司药明康德发布业绩预告，预 计2025年实现归母净利润约191.51亿元，同比增长约102.65%，其中包含了出售联营公司部分股权以及剥离部分业 务所获得的投资收益。照此推算，公司2025年第四季度净利润达到70亿元以上，环比接近翻倍。 值得注意的是，上述协议中所约定的里程碑付款需要满足一定的条件，荣昌生物最终可实现的里程碑付款金额尚 存在不确定性，但6.5亿美元的首付款，系2026年开年以来，现有公开报道中创新药领域BD交易首付款的最高纪 录。 受利好消息影响，1月13日，荣昌生物涨停，创新药板块亦大幅上涨，诺思格、普蕊斯、泓博医药、博济医药等个 股涨停。 2025年，我国创新药产业站在了全球医药创新版图的重要位置。这一年，多款本土研发的PD-1/VEGF双抗产品获 得跨国药企的青睐，凭 ...